NCT04067336 2026-04-21
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Recruiting
Kura Oncology, Inc.
Pfizer
National Cancer Institute (NCI)
Pfizer
AstraZeneca
BioNTech SE
Boehringer Ingelheim
DualityBio Inc.